RRRaynald Roy

Raynald Roy

*This is an algorithmically generated author record based on publicly available information.

Raynald Roy has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • AmpliType® PM and HLA DQα Typing from Pap Smear, Semen Smear, and Postcoital Slides

    by R Roy, R Reynolds

    Deoxyribonucleic acid (DNA) samples extracted from stained pap smear, semen smear and postcoital slides were amplified by the polymerase chain reaction (PCR) and typed for the AmpliType® PM and HLA DQα alleles. HLA DQ α and PM types consistent with blood controls from the donors were obtained. Stained cells fixed to slides can provide a valuable source of material for determining a genetic profile of the sample donor, particularly in sexual assault cases and possibly in missing person cases involving women.


  • Fresh Venous Allografts as Arterial Substitutes in Dogs: The Importance of Donor-Recipient Tissue Compatibility

    by Yves Marois, Robert Guidoin, Eric Wagner, Raynald Roy, Yvan Douville

    Fresh venous allografts were investigated in dogs matched according to donor-recipient tissue compatibility, either originating from the same litter or chosen at random (pound dogs). Five centimeter long segments of femoral vein were interposed as carotid substitutes in an autografting and allografting manner between paired dogs. During a 5-month implantation period, donor-specific antibody development was measured in the recipient serum by a flow-cytometric assay using cultured donor vascular endothelial cells. Autografts and allografts were investigated in terms of patency, histopathology, and endothelial cell function. Fifteen of 16 autografts remained patent. Allografts between littermate dogs, whether compatible or incompatible, showed no donor-specific antibody development and were all patent at retrieval. Compatible and incompatible allografts in littermates did not show any difference in prostacyclin (PGI2)/thromboxane A2 (TXA2) ratios. In pound dogs, both compatible allografts were patent and one dog developed donor-specific antivascular endothelial cell antibodies. Among incompatible dogs, antibody formation was detected at 1 month in five of six recipients and graft patency was as follows: two partial thromboses, two stenoses, and two patent grafts. The PGI2/TXA2 ratio was significantly lower in incompatible allografts than in compatible ones (p = .028). These results show the importance of donor-recipient histocompatibility matching in improving the outcome of vein allografts.


  • Reliability of lymphocyte proliferation assays

    by Lise Fillion, Marthe Belles-Isles, Louise Lemyre, Raynald Roy


  • Use of Myxalin for Improving Vascular Graft Healing: Evaluation of Biocompatibility in Rats

    by Ali Akoum, Yves Marois, Raynald Roy, Martin King, Robert Guidoin, Michel Sigot, Marie-Françoise Sigot Luizard

    Myxalin is a glycopeptide extracted recently from a gram-negative bacterium. It has blood anticoagulant properties and can enhance endothelial cell growth. With the ultimate objective of using this bioactive molecule to promote vascular graft healing, this study assessed its biocompatibility in vivo by comparing the cellular and immunological responses of gelatin-coated knitted polyester grafts with and without myxalin following implantation in the peritoneal cavity of rats for prescheduled periods of 3 days and 1, 2, and 4 weeks. A nongelatin-coated virgin polyester graft was included as the reference material. The biological response to gelatin alone was characterized by a slower rate of cellular infiltration into the implant, reduced collagen synthesis, and higher levels of acid phosphatase and esterase activity in the surrounding tissue. The addition of myxalin to this coating resulted in a significant reduction of hydrolase secretion in the tissue surrounding the implant and an enhancement of cellular ingrowth.